Key result
Interdisciplinary collaboration and attention to CYP450 and P-glycoprotein drug interactions are crucial in cardio-oncology to prevent and reduce drug-related toxicities of cancer treatments.
Why the study?
Cardiovascular disease remains a leading cause of death in cancer survivors, making optimal management of comorbidities and attention to drug-related toxicities and interactions essential in cardio-oncologic care.
Understanding CYP450 and P-glycoprotein mediated drug interactions is essential for preventing cardiotoxicity in patients receiving concurrent cardiology and oncology treatments.
Optimal comorbidity management and drug vigilance matter in cardio-oncology; leaves open standardized interdisciplinary protocols.
Recent advances in treatment have transformed the management of cancer. Despite these advances, cardiovascular disease remains a leading cause of death in cancer survivors. Cardio-oncology has recently evolved as a subspecialty to prevent, diagnose, and manage cardiovascular side effects of antineoplastic therapy. An emphasis on optimal management of comorbidities and close attention to drug interactions are important in cardio-oncologic care. With interdisciplinary collaboration among oncologists, cardiologists, and pharmacists, there is potential to prevent and reduce drug-related toxicities of treatments. The cytochrome P450 (CYP450) family of enzymes and the P-glycoprotein (P-g) transporter play a crucial role in drug metabolism and drug resistance. Here we discuss the role of CYP450 and P-g in drug interactions in the field of cardio-oncology, provide an overview of the cardiotoxicity of a spectrum of cancer agents, highlight the role of precision medicine, and encourage a multidisciplinary treatment approach for patients with cancer.
No takes yet. Share an insight, caveat, or question.
Kamaraju et al. (2021) conducted a review in Cancer and cardiovascular disease. Cardiology and oncology drugs was evaluated. Interdisciplinary collaboration and attention to CYP450 and P-glycoprotein drug interactions are crucial in cardio-oncology to prevent and reduce drug-related toxicities of cancer treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: